"Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses." Nathan and Rossin et al

Published: 22 June 2021| Version 1 | DOI: 10.17632/jst5n87t5p.1
Contributor:
Anusha Nathan

Description

Supplemental Tables S3 and S4 for article titled "Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses." TABLE S3. List of SARS-CoV-2 epitopes tested by HLA class I-peptide stability assay. Each row indicates a highly networked SARS-CoV-2 epitope and columns include the following: HLA, Peptide #, Epitope Code, Epitope Sequence, Gene, Amino Acid, Protein, Protein Region, Network Score, NetMHC Binding Score, HLA Stabilization, 50% Experimental Binder (YES/NO). TABLE S4. Sequences of Highly Networked HLA stabilizing SARS-CoV-2 Epitopes in the B.1.117, B.1.351, P.1 and B.1.617 Variants, Related to Figure 3. Mutations from ancestral strain delineated in bold. Each row indicates a highly networked SARS-CoV-2 epitope and columns include the following: Epitope Code, WT Epitope Sequence, B.1.1.7 (UK Variant), B.1.351 (South African Variant), P.1 (Brazilian Variant), B.1.617 (Indian Variant), Protein, Protein Region, Amino Acid, Network Score. Please contact Anusha Nathan at anusha_nathan@hms.harvard.edu with questions.

Files

Institutions

Ragon Institute, Massachusetts Institute of Technology, Harvard University

Categories

Immunology, Vaccine, T Cell, Severe Acute Respiratory Syndrome Coronavirus 2, COVID-19

Licence